Mukesh Verma, Ph.D.
Branch Chief, Methods and Technologies Branch

Photo of Mukesh Verma

National Institutes of Health
National Cancer Institute
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
9609 Medical Center Drive, Rm. 4E102, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)


  • Ph.D. - Host-virus Interaction
    Banaras Hindu University
  • M.Sc. - Biochemistry (Major) and Microbiology (Minor)
    Pantnagar University
  • B.Sc. - Biological Sciences
    Meerut University

Interest Areas

  • Biomarkers
  • Epigenetics
  • Epidemiology Technologies
  • Proteomics
  • MicroRNA
  • Methylation
  • Mitochondria
  • Nanotechnology
  • Risk Assessment
  • Susceptibility Factors
  • Systems Genetics
  • Metabolomics


Dr. Verma is Chief of the Epidemiology and Genomics Research Program's (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility.

He is responsible for stimulating EGRP-funded research on epigenetic approaches in cancer epidemiology and has been instrumental in developing epigenetics research for NIH as a whole. Dr. Verma helped to develop a Request for Applications (RFA) on Environmental Influences on Epigenetics with the National Institute of Environmental Health Sciences (NIEHS) and represents the Division of Cancer Control and Population Sciences (DCCPS), in NIH's Roadmap Initiative on EpigeneticsExternal Web Site Policy. He helped develop an RFA on Comparative Systems Genetics of Cancer with NCI's Division of Cancer Biology (DCB), and is known within the extramural research community as an EGRP Program Director for Program Announcements (PAs) on Small Grants for Cancer Epidemiology and Pilot Studies in Pancreatic Cancer. He also organized a workshop to explore developing a concept for a research initiative on mitochondrial DNA and cancer epidemiology.

Dr. Verma was, and continues to be, a co-Program Director for initiatives in gene-environment interactions in cancer etiology, including the Breast and Prostate Cancer and Hormone-Related Variants Cohort Consortium (BPC3), which is a collaborative project to pool data and biospecimens from a group of large prospective cancer epidemiology cohorts.

Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP's former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI's Division of Cancer Prevention (DCP), where he worked in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.


Verma M. The Human Epigenome and Cancer. In: Khoury M, Bedrosian S, Gwinn M, Higgins J, Ioannidis J, Little J, eds. Human Genome Epidemiology: Building the evidence for using genetic information to improve health and prevent disease. 2nd ed. New York, NY: Oxford University Press, Inc.; 2010: 551-578.

Mishra A, Verma M. Cancer Biomarkers: Are We Ready for the Prime Time?External Web Site Policy Cancers. 2010 Mar; 2(1): 190-208.

Verma M. Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and EpidemiologyExternal Web Site Policy. Cancers. 2010 Nov; 2(4): 1830-1837.

Verma M. Nutritional epigenetics and disease prevention: are we there yet? In: Maulik N, Maulik G, eds. Nutrition, Epigenetic Mechanisms, and Human Disease. Boca Raton, FL: CRC Press Taylor & Francis Group; 2011: 1-11.

Banerjee H, Verma M. Quantum dots and their potential applications in cancer detection and therapyExternal Web Site Policy. Int. J. of Biomedical Nanoscience and Nanotechnology. 2011; 2(1): 33-44.

Verma M. Epigenome-Wide Association Studies (EWAS) in CancerExternal Web Site Policy. Curr Genomics. 2012 Jun; 13(4): 308-313.

Verma M, Banaudha K. Application of cancer toxocoepigenomics in identifying high risk populationsExternal Web Site Policy. In: Sahu SC, ed. Toxicology and Epigenetics. Chichester, UK: John Wiley and Sons, Ltd.; 2012: 645-652.

Verma M, Khoury M J, and Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profilingExternal Web Site Policy. Cancer Epidemiol Biomarkers Prev. 2013 Feb; 22(2): 189-200.

Verma M. Cancer control and prevention: nutrition and epigeneticsExternal Web Site Policy. Curr Opin Clin Nutr Metab Care. 2013 Jul; 16(4): 376-384.

Return to Top